These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24293233)

  • 1. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
    Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R
    J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
    Lombardi G; Bellu L; Pambuku A; Della Puppa A; Fiduccia P; Farina M; D'Avella D; Zagonel V
    J Neurooncol; 2016 Jul; 128(3):481-6. PubMed ID: 27165580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
    Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
    Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
    Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
    Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Franceschi E; Blatt V; Santoro A; Faedi M; Amistà P; Gardiman M; Labianca R; Bianchini C; Ermani M; Reni M
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):769-75. PubMed ID: 19169684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
    Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
    Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
    Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
    J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
    Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L
    J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
    Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
    Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.
    Lombardi G; Farina P; Della Puppa A; Cecchin D; Pambuku A; Bellu L; Zagonel V
    Biomed Res Int; 2014; 2014():698542. PubMed ID: 24800248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
    Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
    J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
    Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
    Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and daily temozolomide for recurrent glioblastoma.
    Desjardins A; Reardon DA; Coan A; Marcello J; Herndon JE; Bailey L; Peters KB; Friedman HS; Vredenburgh JJ
    Cancer; 2012 Mar; 118(5):1302-12. PubMed ID: 21792866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
    Franceschi E; Lamberti G; Paccapelo A; Di Battista M; Genestreti G; Minichillo S; Mura A; Bartolini S; Agati R; Brandes AA
    J Neurooncol; 2018 Sep; 139(2):383-388. PubMed ID: 29671196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
    Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
    Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD
    J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
    Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
    Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
    Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
    Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
    Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
    Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA
    Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.